Gateway to Think Tanks
来源类型 | Working Paper |
规范类型 | 报告 |
DOI | 10.3386/w20005 |
来源ID | Working Paper 20005 |
Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market | |
Eric Helland; Darius N. Lakdawalla; Anup Malani; Seth A. Seabury | |
发表日期 | 2014-03-20 |
出版年 | 2014 |
语种 | 英语 |
摘要 | In a complex economy, production is vertical and crosses jurisdictional lines. Goods are often produced by a global or national firm upstream and improved or distributed by local firms downstream. In this context, heightened products liability may have unintended consequences for consumer safety. Conventional wisdom holds that an increase in tort liability on the upstream firm will encourage that firm to improve safety for consumers. However, in the real-world, policy actions in a single jurisdiction may not be significant enough to influence the behavior of an upstream firm that produces for many jurisdictions. Even worse, if liability is shared between upstream and downstream firms, higher upstream liability may decrease the liability of the downstream distributor and encourage it to behave more recklessly. In this manner, higher upstream liability may perversely increase the sales of a risky good. We demonstrate this phenomenon in the context of the pharmaceutical market. We show that higher products liability on upstream pharmaceutical manufacturers reduces the liability faced by downstream doctors, who respond by prescribing more drugs than before. |
主题 | Public Economics ; Subnational Fiscal Issues ; Health, Education, and Welfare ; Health ; Other ; Law and Economics |
URL | https://www.nber.org/papers/w20005 |
来源智库 | National Bureau of Economic Research (United States) |
引用统计 | |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/577679 |
推荐引用方式 GB/T 7714 | Eric Helland,Darius N. Lakdawalla,Anup Malani,et al. Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market. 2014. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。